Assyro AI

FDA Orange Book · active-ingredient family

Teduglutide

Teduglutide is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:GATTEX KIT · NDA 203441

1

Brand (NDA)

0

Generics (ANDA)

4

Listed patents

1

Exclusivity periods

Brand (NDA) products · powder

ProductApplicantApplicationTEApproved
GATTEX KITRLDTAKEDA PHARMS USANDA 203441Dec 21, 2012

Marketing exclusivity (1)

  • ODE-240Orphan-drug exclusivity (7 years)

    May 16, 2026

    1 mo ago

Listed patents (4)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
9060992Nov 01, 20258 mo ago
U-1320Delisted
7847061Nov 01, 20258 mo ago
U-1320Delisted
7847061*PEDMay 01, 20262 mo ago
9060992*PEDMay 01, 20262 mo ago

Teduglutide — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.